有投资者向复星医药提问, 请问复星管理层截止2024年三季度公司总负责的加权成本率是多少?总资产收益率率是多少?公司通过负债所获取的收益是否可以覆盖总负债的资金成本?公司管理层的盲目扩张,高溢价收购的目的是什么?管理层高管千万年薪持股比例却非常低,长期看管理层是否和股东利益一致?是否存在损害股东利益的可能(例如高溢价收购,减少研发投入,关联交易等)。公司是否考虑高管年薪的一半通过股票发放,毕竟同股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.